Hanson & Doremus Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

Hanson & Doremus Investment Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,000	Closed	-$14K	–	479
2024 Q1	$14K	Buy	+1,000	New	+$14.5K	﹤0.01%	389
2019 Q3	–	Sell	-557	Closed	-$10K	–	472
2019 Q2	$10K	Sell	557 -456	-45%	-$8.3K	﹤0.01%	417
2019 Q1	$21K	Buy	+1,013	New	+$20.4K	0.01%	353

Other funds holding TAK

GAM

Groupama Asset Management Paris, France $6.85B AUM 43.37% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Hanson & Doremus Investment Management's TAK Position: Q2 2024 in Review

Hanson & Doremus Investment Management sold out of Takeda Pharmaceutical (TAK) in Q2 2024, closing a stake of 1,000 shares — an estimated $14K sold.

Hanson & Doremus Investment Management first reported a position in TAK in Q1 2019 and held it in 3 quarters. The position peaked at $21K in Q1 2019. 284 funds tracked by Wall St. Rank hold TAK as of Q2 2024.

Hanson & Doremus Investment Management reported no remaining Takeda Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Hanson & Doremus Investment Management sold 1,000 Takeda Pharmaceutical shares in Q2 2024, an estimated $14K.
Hanson & Doremus Investment Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 3 quarters.
Hanson & Doremus Investment Management's Takeda Pharmaceutical position peaked at $21K in Q1 2019.
284 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2024.

Based on Hanson & Doremus Investment Management's 13F filing for Q2 2024, filed 8 Aug 2024.